

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) An isolated rat prostate apoptosis responsive 4 (Par-4) protein fragment selected from the group consisting of amino acids 1-204, 137-221, 137-213, 137-198 and 137-195 of the Par-4 protein (SEQ ID NO: 1) wherein the Par-4 protein fragment is effective in reducing the size of tumors resistant to apoptosis by Par-4.

Claim 2-5 (Cancelled)

6. (Previously Presented) An isolated fusion polypeptide comprising a Par-4 fragment selected from the group consisting of amino acids 1-204, 137-221, 137-213, 137-198 and 137-195 of Par-4 protein (SEQ ID NO: 1).

7. (Currently Amended) A method of producing a polypeptide, comprising incubating a host cell comprising a nucleic acid encoding the Par-4 protein fragment of claim 1 in operable linkage with a promoter under conditions that permit expression of the Par-4 protein fragment.

8. (Withdrawn) A method of producing a polypeptide, comprising incubating a cell of claim 5 under conditions that permit expression of one or more polypeptides encoded by the nucleic acid.

Claim 9 (Cancelled)

10. (Withdrawn) A method of screening for therapeutic agents comprising selecting an X-associated specific sequence as a target sequence; contacting a test

compound with the target sequence; and selecting as candidate therapeutic agents those test compounds which bind to the target sequence.

11. (Withdrawn) The method of claim 9, wherein the sequence is a polypeptide encoded by one or more sequences of claim 3.

Claims 12-17 (Cancelled)

18. (Withdrawn-Previously Presented) A method of treating cancer in a subject suffering therefrom, comprising administering to the subject a modified Par-4 protein selected from the group consisting of amino acids 1-204, 137-221, 137-213, 137-198 and 137-195 of the Par-4 protein (SEQ ID NO: 1), wherein the administration of the Par-4 protein causes reduction of tumors resistant to apoptosis by Par-4.

19. (Withdrawn) The method of claim 18, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer and lung cancer.

20. (Withdrawn) The method of claim 18, wherein the subject is selected from the group consisting of a canine, a feline, an ovine, a primate, an equine, a porcine, a caprine, a camelid, an avian, a bovine, amphibian, fish or a murine organism.

21. (Withdrawn) The method of claim 20, wherein the subject is a primate.

22. (Withdrawn) The method of claim 21, wherein the subject is human.

23. (Withdrawn) The method of claim 18, wherein the Par-4 mutant a mutant of Par-4 selected from the group consisting of 1-204, 137-221, 137-213, 137-198 and 137-195.

24. (Currently Amended) A pharmaceutical composition for the treatment of cancer, comprising an isolated and purified ~~modified~~ Par-4 protein selected from the group consisting of amino acids 1-204, 137-221, 137-213, 137-198 and

137-195 of the Par-4 protein (SEQ ID NO: 1), and a pharmaceutically acceptable diluent, carrier or excipient.